RedHill Biopharma Ltd (RDHL)

[noretreat]

I still contend that results were very good. It is rare in a phase 2 to see a test drug significantly beat the standard of care. In this case, Redhill directionally did better than the two leading drugs in the category but as usual results were not significant due to small sample size and somewhat different test design. Results certainly suggest moving forward with phase 3. Similar percentages with larger samples would produce significant differences in phase three.

Importantly, this will likely not be among the earliest revenue generators for Redhill. There are several drugs already being sold and more coming that are well into phase three.